Summary of Adrenoleukodystrophy Global Clinical Trials 2015 - ref #GB000024
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2015
GlobalData's clinical trial report, “Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2015" provides an overview of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) clinical trials scenario. This report provides top line data relating to the clinical trials on Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Clinical Trials by G7 Countries: Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials 17
Clinical Trials by Phase 18
In Progress Trials by Phase 19
Clinical Trials by Trial Status 20
Clinical Trials by End Point Status 21
Unaccomplished Trials of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) 22
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials 28
Prominent Drugs 29
Clinical Trial Profiles 30
Clinical Trial Overview of Top Companies 30
Bluebird bio, Inc. 30
Clinical Trial Overview of Bluebird bio, Inc. 30
Aldagen, Inc. (Inactive) 31
Clinical Trial Overview of Aldagen, Inc. (Inactive) 31
NUVISAN GmbH 32
Clinical Trial Overview of NUVISAN GmbH 32
Nutra Pharma Corporation 33
Clinical Trial Overview of Nutra Pharma Corporation 33
Nuo Therapeutics, Inc. 34
Clinical Trial Overview of Nuo Therapeutics, Inc. 34
Neuralgene 35
Clinical Trial Overview of Neuralgene 35
Marcus Foundation Inc 36
Clinical Trial Overview of Marcus Foundation Inc 36
Fate Therapeutics, Inc. 37
Clinical Trial Overview of Fate Therapeutics, Inc. 37
Celgene Corporation 38
Clinical Trial Overview of Celgene Corporation 38
Asklepion Pharmaceuticals, LLC 39
Clinical Trial Overview of Asklepion Pharmaceuticals, LLC 39
Clinical Trial Overview of Top Institutes / Government 40
Duke University 40
Clinical Trial Overview of Duke University 40
Hugo W. Moser Research Institute at Kennedy Krieger, Inc. 41
Clinical Trial Overview of Hugo W. Moser Research Institute at Kennedy Krieger, Inc. 41
Academic Medical Center 42
Clinical Trial Overview of Academic Medical Center 42
Far Eastern Memorial Hospital 43
Clinical Trial Overview of Far Eastern Memorial Hospital 43
FDA Office of Orphan Products Development 44
Clinical Trial Overview of FDA Office of Orphan Products Development 44
Herbert Irving Comprehensive Cancer Center 45
Clinical Trial Overview of Herbert Irving Comprehensive Cancer Center 45
Institute of Biomedical Investigations of Bellvitge 46
Clinical Trial Overview of Institute of Biomedical Investigations of Bellvitge 46
Masonic Cancer Center 47
Clinical Trial Overview of Masonic Cancer Center 47
Five Key Clinical Profiles 48
Appendix 67
Abbreviations 67
Definitions 67
Research Methodology 68
Secondary Research 68
About GlobalData 69
Contact Us 69
Disclaimer 69
Source 70
List of Tables
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Region, 2015* 8
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 9
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 10
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 11
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Europe, Top Countries, 2015* 12
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, North America, Top Countries, 2015* 13
Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials, G7 Countries (%), 2015* 14
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials, E7 Countries (%), 2015* 17
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Phase, 2015* 18
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 19
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 20
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 21
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Suspended Clinical Trials, 2015* 22
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Withdrawn Clinical Trials, 2015* 23
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Terminated Clinical Trials, 2015* 24
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 25
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 26
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Bluebird bio, Inc., 2015* 30
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Aldagen, Inc. (Inactive), 2015* 31
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by NUVISAN GmbH, 2015* 32
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Nutra Pharma Corporation, 2015* 33
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Nuo Therapeutics, Inc., 2015* 34
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Neuralgene, 2015* 35
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Marcus Foundation Inc, 2015* 36
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fate Therapeutics, Inc., 2015* 37
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2015* 38
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Asklepion Pharmaceuticals, LLC, 2015* 39
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2015* 40
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Hugo W. Moser Research Institute at Kennedy Krieger, Inc., 2015* 41
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Academic Medical Center, 2015* 42
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Far Eastern Memorial Hospital, 2015* 43
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by FDA Office of Orphan Products Development, 2015* 44
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Herbert Irving Comprehensive Cancer Center, 2015* 45
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Institute of Biomedical Investigations of Bellvitge, 2015* 46
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Masonic Cancer Center, 2015* 47
List of Figures
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Region (%), 2015* 8
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 9
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 10
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Europe, Top Countries (%), 2015* 12
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 13
Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials, G7 Countries (%), 2015* 14
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials, E7 Countries (%), 2015* 17
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 18
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 19
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 20
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 21
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 25
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 26
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28
Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29
GlobalData Methodology 68
Publisher: GlobalData
Publication date: August 2015
Terms and Conditions
GLOBALDATA TERMS AND CONDITIONS
Single Copy Report Products
GlobalData Ltd (“Holding Company”), a company registered in England with the company number 05968121 and registered office at John Carpenter House, John Carpenter Street, London, EC4Y 0AN, United Kingdom. These terms and conditions and the Order Form comprise the agreement pursuant to which Company provides the Product (defined below) to you ("Agreement"). "We", "us", "our" or “GlobalData” refers to Company. "You" or "your" refers to the person who (or on whose behalf) an Order is placed and includes your legal successors and permitted assigns.
1. Order Forms: Order Forms shall only be binding when accepted by us. You shall not cancel or amend an Order Form unless we have given our prior written consent. We shall assume that any person who places an Order Form on your behalf can bind you legally.
2. Ownership: The legal and beneficial interest in all copyrights, patents, trade marks, service marks, design rights (whether registered or unregistered), database rights, proprietary information rights and all other proprietary rights as may exist anywhere in the world together with applications associated with any such rights ("Intellectual Property Rights") relating to the Product belong to us, the holding company, or our licensors, as the case may be, at all times. You obtain no ownership rights in the Product or any of the Intellectual Property Rights pursuant to or arising out of this Agreement.
3. Grant of License: We grant you a non exclusive, non transferable license to use the products described in the Order Form ("Product"). You warrant that you shall only use the Product for your business purposes in accordance with this agreement and shall not, without our prior written consent, make available, copy, reproduce, retransmit, disseminate, sell, license, distribute, publish, broadcast or otherwise circulate the Product (or any part of it) to any person other than in accordance with these terms and conditions. You further warrant that you shall comply with all applicable laws and regulations and shall not knowingly use the Product for any improper or unlawful purposes.
4. License: Unless stated otherwise on the Order Form the Product is licensed to you on a single user basis. Only the user named on the Order Form as the customer may use the product as outlined in this agreement. Additional user licenses may be purchased by you at our prevailing standard list prices for single users or by the purchase of a site wide or enterprise wide license. You warrant that you will use appropriate controls to ensure that the license is not breached by you or by other users and agree that any breach may cause us irrepreable harm. You agree we have the right to charge additional fees for unauthorized usage in line with our standard list prices. This clause survives termination of the Agreement.
5. Fees and Payment Terms: Payment is due in full prior to delivery of any product. We shall invoice you for fees payable by you to us under this Agreement ("Fees") upon our acceptance of an Order Form. Unless indicated otherwise on the Order Form you will pay all invoices on receipt of that invoice. We may issue the invoice in print and/or electronic form. Unless expressly provided the fees exclude any sales, use, excise, or other applicable taxes. You will pay or reimburse us for any such taxes for which either party may become held responsible for. A fee for late payment will be assessed equal to the lower of one and one half percent (1.5%) per month and the maximum permitted by law. In addition you agree that all sales are final and that you may not request a refund. We reserve the right, for any reason whatsoever, to withold delivery of the Product to you until payment has been received in full.
6. Warranties: We shall use best endeavors to ensure the Product is provided to you in accordance with any specifications set out in the Order Form and accepted by us. We do not warrant that the Product will meet your requirements or that it will be complete, error free or delivered without interruption. Findings, conclusions and recommendations in the Product are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such, we can accept no liability whatsoever for actions taken based on any information that may subsequently prove to be incorrect. Except as expressly set out in this Agreement, all express or implied representations, warranties, conditions and undertakings are excluded to the maximum extent permissible by law. You assume sole responsibility for the selection, suitability and use of the Product and acknowledge that except as stated above we do not provide any additional warranties or guarantees relating to the Product. This clause survives termination of the Agreement.
7. Indemnification. Generally. We and You (“Both Parties”) will, to the extent permitted by law, indemnify, defend and hold harmless the other party from and against any and all claims, demands, complaints, or actions of third parties (including employees of the parties) arising from or relating to this agreement, including personal injury, death and property damage to the extent caused or arising out of the violation of law, gross negligence, fraud, willful misconduct or breach of this agreement. In the event that both parties are at fault they will indemnify each other in proportion to their relative negligence. In addition we will indemnify, defend and hold harmless, you from and against any and all claims, demands, complaints or actions of third parties (including employees of the parties) arising from or relating to this agreement brought against you alleging that the product infringe any patent, copyright, trademark, trade secret or other intellectual property right. Our obligations under this section are conditioned on you i) Promptly notifying us of any claim, ii) Granting us sole control over the defense and settlement of the action. iii) Reasonably cooperating with us in connection with such action at our expense, iv) Abetting no such claim, demand, complaint or action v) Neither modifying or using the product nor breaching this agreement in a manner for which no infringement would have occurred. If the product becomes or in our opinion is likely to become the subject of such a claim, then in lieu of the indemnity we may, at our expense, i) procure you the right to license using or receiving the product free of any such liability, ii) replace or modify in whole or part the product to make them non-infringing without degradation or iii) refund you a pro-rata portion of the fee.
8. Limitation of liability: Neither party shall be liable under this agreement to the other party for indirect, special, exemplary, punitive or consequential damages including without limitation loss of goodwill, whether arising from negligence, breach of contract or otherwise. Our liability in contract, tort or otherwise arising out of or in connection with the Agreement shall in respect of any one or more incidents not exceed the total fees received by us from you for the Product in the 12 months prior to the date the incident occurs. This clause shall survive termination of the Agreement.
9. Confidentiality: Neither party shall, except as required to perform our and / or your respective rights and obligations, use, copy, adapt, alter, disclose to any third party or part with possession of any information or data of the other party which is disclosed or otherwise comes into our or your possession directly or indirectly as a result of these Terms and which is of a confidential nature, in writing marked confidential or, if disclosed orally, reduced to writing and marked confidential within 30 days of the date of such disclosure ("Information"). This obligation shall not apply to Information:
a. the receiving party can prove was in its possession at the date it was received or obtained; or
b. the receiving party obtains from some person other than us, you or an Affiliate with good legal title thereto; or
c. comes into the public domain otherwise than through the default or negligence of the receiving party; or
d. is independently developed by or for the receiving party.
10. Solicitation. You agree that for a period of twelve (12) months immediately following the delivery of the products purchased, for any reason, whether with or without cause, you shall not either directly or indirectly solicit, induce, recruit or encourage any of the Company’s employees, who were involved in the sale, marketing, support or production of the product used, to leave their employment, or attempt to solicit, induce, recruit, encourage or take away employees of the Company.
11. Force Majeure: We shall not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, including but not limited to, earthquake, fire, flood or any other natural disaster, labor dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
12. Further Provisions: The Agreement constitutes the entire understanding between the parties relating to the Product and supersedes all previous agreements and understandings whether oral or written relating to the Product. In the event of any inconsistency between these terms and conditions and the Order, the Order shall prevail. The Agreement may only be varied in writing signed by an authorized representative of each party. Failure at any time to enforce any of these terms and conditions or to require performance by the other party of any such term or condition shall not be construed as a waiver of such provision or affect the right of either party to enforce the same. If any provision is held to be invalid or unenforceable by any tribunal of competent jurisdiction, the remaining provisions shall not be affected and shall be carried out as closely as possible according to the original intent. The Agreement does not confer any rights to or on any third party. The Agreement shall be governed by the laws of England and Wales. The parties irrevocably agree to the exclusive jurisdiction of the Courts of England.
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
